Cargando…

Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing

PURPOSE: Given regulatory approval of immune checkpoint inhibitors in patients with mismatch repair–deficient (MMR-D) cancers agnostic to tumor type, it has become important to characterize occurrence of MMR-D and develop cost-effective screening approaches. Using a next-generation sequencing (NGS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Albayrak, Adem, Garrido-Castro, Ana C., Giannakis, Marios, Umeton, Renato, Manam, Monica Devi, Stover, Elizabeth H., Porter, Rebecca L., Johnson, Bruce E., Liaw, Kai-Li, Amonkar, Mayur, Church, Alanna J., Janeway, Katherine A., Nowak, Jonathan A., Sholl, Lynette, Lin, Nancy U., Johnson, Jason M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445788/
https://www.ncbi.nlm.nih.gov/pubmed/35050773
http://dx.doi.org/10.1200/PO.20.00185
_version_ 1785094255258107904
author Albayrak, Adem
Garrido-Castro, Ana C.
Giannakis, Marios
Umeton, Renato
Manam, Monica Devi
Stover, Elizabeth H.
Porter, Rebecca L.
Johnson, Bruce E.
Liaw, Kai-Li
Amonkar, Mayur
Church, Alanna J.
Janeway, Katherine A.
Nowak, Jonathan A.
Sholl, Lynette
Lin, Nancy U.
Johnson, Jason M.
author_facet Albayrak, Adem
Garrido-Castro, Ana C.
Giannakis, Marios
Umeton, Renato
Manam, Monica Devi
Stover, Elizabeth H.
Porter, Rebecca L.
Johnson, Bruce E.
Liaw, Kai-Li
Amonkar, Mayur
Church, Alanna J.
Janeway, Katherine A.
Nowak, Jonathan A.
Sholl, Lynette
Lin, Nancy U.
Johnson, Jason M.
author_sort Albayrak, Adem
collection PubMed
description PURPOSE: Given regulatory approval of immune checkpoint inhibitors in patients with mismatch repair–deficient (MMR-D) cancers agnostic to tumor type, it has become important to characterize occurrence of MMR-D and develop cost-effective screening approaches. Using a next-generation sequencing (NGS) panel (OncoPanel), we developed an algorithm to identify MMR-D frequency in tumor samples and applied it in a clinical setting with pathologist review. METHODS: To predict MMR-D, we adapted methods described previously for use in NGS panels, which assess patterns of single base-pair insertion or deletion events occurring in homopolymer regions. Tumors assayed with OncoPanel between July 2013 and July 2018 were included. For tumors tested after June 2017, sequencing results were presented to pathologists in real time for clinical MMR determination, in the context of tumor mutation burden, other mutational signatures, and clinical data. RESULTS: Of 20,301 tumors sequenced, 2.7% (553) were retrospectively classified as MMR-D by the algorithm. Of 4,404 samples with pathologist sign-out of MMR status, the algorithm classified 147 (3.3%) as MMR-D: in 116 cases, MMR-D was confirmed by a pathologist, five cases were overruled by the pathologist, and 26 were assessed as indeterminate. Overall, the highest frequencies of OncoPanel-inferred MMR-D were in endometrial (21%; 152/723), colorectal (9.7%; 169/1,744), and small bowel (9.3%; 9/97) cancers. When algorithm predictions were compared with historical MMR immunohistochemistry or polymerase chain reaction results in a set of 325 tumors sequenced before initiation of pathologist assessment, the overall sensitivity and specificity of the algorithm were 91.1% and 98.2%, respectively. CONCLUSION: We show that targeted, tumor-only NGS can be leveraged to determine MMR signatures across tumor types, suggesting that broader biomarker screening approaches may have clinical value.
format Online
Article
Text
id pubmed-10445788
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-104457882023-08-24 Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing Albayrak, Adem Garrido-Castro, Ana C. Giannakis, Marios Umeton, Renato Manam, Monica Devi Stover, Elizabeth H. Porter, Rebecca L. Johnson, Bruce E. Liaw, Kai-Li Amonkar, Mayur Church, Alanna J. Janeway, Katherine A. Nowak, Jonathan A. Sholl, Lynette Lin, Nancy U. Johnson, Jason M. JCO Precis Oncol ORIGINAL REPORTS PURPOSE: Given regulatory approval of immune checkpoint inhibitors in patients with mismatch repair–deficient (MMR-D) cancers agnostic to tumor type, it has become important to characterize occurrence of MMR-D and develop cost-effective screening approaches. Using a next-generation sequencing (NGS) panel (OncoPanel), we developed an algorithm to identify MMR-D frequency in tumor samples and applied it in a clinical setting with pathologist review. METHODS: To predict MMR-D, we adapted methods described previously for use in NGS panels, which assess patterns of single base-pair insertion or deletion events occurring in homopolymer regions. Tumors assayed with OncoPanel between July 2013 and July 2018 were included. For tumors tested after June 2017, sequencing results were presented to pathologists in real time for clinical MMR determination, in the context of tumor mutation burden, other mutational signatures, and clinical data. RESULTS: Of 20,301 tumors sequenced, 2.7% (553) were retrospectively classified as MMR-D by the algorithm. Of 4,404 samples with pathologist sign-out of MMR status, the algorithm classified 147 (3.3%) as MMR-D: in 116 cases, MMR-D was confirmed by a pathologist, five cases were overruled by the pathologist, and 26 were assessed as indeterminate. Overall, the highest frequencies of OncoPanel-inferred MMR-D were in endometrial (21%; 152/723), colorectal (9.7%; 169/1,744), and small bowel (9.3%; 9/97) cancers. When algorithm predictions were compared with historical MMR immunohistochemistry or polymerase chain reaction results in a set of 325 tumors sequenced before initiation of pathologist assessment, the overall sensitivity and specificity of the algorithm were 91.1% and 98.2%, respectively. CONCLUSION: We show that targeted, tumor-only NGS can be leveraged to determine MMR signatures across tumor types, suggesting that broader biomarker screening approaches may have clinical value. American Society of Clinical Oncology 2020-09-21 /pmc/articles/PMC10445788/ /pubmed/35050773 http://dx.doi.org/10.1200/PO.20.00185 Text en © 2020 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle ORIGINAL REPORTS
Albayrak, Adem
Garrido-Castro, Ana C.
Giannakis, Marios
Umeton, Renato
Manam, Monica Devi
Stover, Elizabeth H.
Porter, Rebecca L.
Johnson, Bruce E.
Liaw, Kai-Li
Amonkar, Mayur
Church, Alanna J.
Janeway, Katherine A.
Nowak, Jonathan A.
Sholl, Lynette
Lin, Nancy U.
Johnson, Jason M.
Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing
title Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing
title_full Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing
title_fullStr Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing
title_full_unstemmed Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing
title_short Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing
title_sort clinical pan-cancer assessment of mismatch repair deficiency using tumor-only, targeted next-generation sequencing
topic ORIGINAL REPORTS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445788/
https://www.ncbi.nlm.nih.gov/pubmed/35050773
http://dx.doi.org/10.1200/PO.20.00185
work_keys_str_mv AT albayrakadem clinicalpancancerassessmentofmismatchrepairdeficiencyusingtumoronlytargetednextgenerationsequencing
AT garridocastroanac clinicalpancancerassessmentofmismatchrepairdeficiencyusingtumoronlytargetednextgenerationsequencing
AT giannakismarios clinicalpancancerassessmentofmismatchrepairdeficiencyusingtumoronlytargetednextgenerationsequencing
AT umetonrenato clinicalpancancerassessmentofmismatchrepairdeficiencyusingtumoronlytargetednextgenerationsequencing
AT manammonicadevi clinicalpancancerassessmentofmismatchrepairdeficiencyusingtumoronlytargetednextgenerationsequencing
AT stoverelizabethh clinicalpancancerassessmentofmismatchrepairdeficiencyusingtumoronlytargetednextgenerationsequencing
AT porterrebeccal clinicalpancancerassessmentofmismatchrepairdeficiencyusingtumoronlytargetednextgenerationsequencing
AT johnsonbrucee clinicalpancancerassessmentofmismatchrepairdeficiencyusingtumoronlytargetednextgenerationsequencing
AT liawkaili clinicalpancancerassessmentofmismatchrepairdeficiencyusingtumoronlytargetednextgenerationsequencing
AT amonkarmayur clinicalpancancerassessmentofmismatchrepairdeficiencyusingtumoronlytargetednextgenerationsequencing
AT churchalannaj clinicalpancancerassessmentofmismatchrepairdeficiencyusingtumoronlytargetednextgenerationsequencing
AT janewaykatherinea clinicalpancancerassessmentofmismatchrepairdeficiencyusingtumoronlytargetednextgenerationsequencing
AT nowakjonathana clinicalpancancerassessmentofmismatchrepairdeficiencyusingtumoronlytargetednextgenerationsequencing
AT sholllynette clinicalpancancerassessmentofmismatchrepairdeficiencyusingtumoronlytargetednextgenerationsequencing
AT linnancyu clinicalpancancerassessmentofmismatchrepairdeficiencyusingtumoronlytargetednextgenerationsequencing
AT johnsonjasonm clinicalpancancerassessmentofmismatchrepairdeficiencyusingtumoronlytargetednextgenerationsequencing